Sequential changes of serum ferritin levels and their clinical significance in lamivudine-treated patients with chronic viral hepatitis B

Table 1 Sequential changes and comparisons of serum ferritin levels (μg/L) at different time points during lamivudine treatment between patients negative and positive for HBV DNA at end of treatment

Group	Baseline	Months after treatment
		3	6	12
HBV DNA ( - ) group (n = 19)	231.20 ± 182.50	130.51 ± 110.21	96.25 ± 68.03	110.78 ± 83.37
HBV DNA ( + ) group (n = 19)	187.42 ± 103.60	182.44 ± 107.15	154.92 ± 66.62	141.28 ± 86.48
P values	0.371	0.150	0.013	0.283

Table 2 Sequential changes and comparisons of serum ferritin levels (μg/L) at different time points during lamivudine treatment in HBeAg-negative and -positive groups at end of treatment

Group	Baseline	Months after treatment
		3	6	12
HBV DNA ( - ) group (n = 12)	250.16 ± 190.78	135.72 ± 138.33	106.13 ± 74.10	97.80 ± 76.96
HBV DNA ( + ) group (n = 26)	190.45 ± 123.50	166.05 ± 96.51	35.31 ± 71.60	140.18 ± 87.40
P values	0.336	0.439	0.262	0.160

Table 3 Sequential changes and comparisons of serum ferritin levels (μg/L) at different time points during lamivudine treatment in HBeAb-negative and -positive groups at end of treatment

Group	Baseline	Months after treatment
		3	6	12
HBV DNA ( - ) group (n = 10)	249.19 ± 176.48	147.33 ± 147.60	114.47 ± 76.62	104.41 ± 78.60
HBV DNA ( + ) group (n = 28)	195.07 ± 137.31	159.74 ± 96.94	129.85 ± 72.26	134.61 ± 87.51
P values	0.328	0.765	0.577	0.346

Table 4 Sequential changes and comparisons of serum ferritin levels (μg/L) at different time points during lamivudine treatment in patients with normalized serum ALT and those with abnormal ALT at end of treatment

Group	Baseline	Months after treatment
		3	6	12
HBV DNA ( - ) group (n = 19)	198.40 ± 161.58	139.39 ± 111.3	112.35 ± 57.51	99.19 ± 60.52
HBV DNA ( + ) group (n = 19)	220.22 ± 136.72	173.56 ± 109.68	140.37 ± 86.07	155.21 ± 98.94
P values	0.656	0.347	0.266	0.048